Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Operating Leases: 2021-2024

Historic Operating Leases for Nurix Therapeutics (NRIX) over the last 4 years, with Nov 2024 value amounting to $20.3 million.

  • Nurix Therapeutics' Operating Leases rose 155.93% to $52.7 million in Q3 2025 from the same period last year, while for Aug 2025 it was $52.7 million, marking a year-over-year increase of 155.93%. This contributed to the annual value of $20.3 million for FY2024, which is 12.26% down from last year.
  • According to the latest figures from FY2024, Nurix Therapeutics' Operating Leases is $20.3 million, which was down 12.26% from $23.1 million recorded in FY2023.
  • In the past 5 years, Nurix Therapeutics' Operating Leases ranged from a high of $23.1 million in FY2023 and a low of $6.4 million during FY2022.
  • In the last 3 years, Nurix Therapeutics' Operating Leases had a median value of $20.3 million in 2024 and averaged $16.6 million.
  • As far as peak fluctuations go, Nurix Therapeutics' Operating Leases dropped by 29.98% in 2022, and later surged by 259.42% in 2023.
  • Yearly analysis of 4 years shows Nurix Therapeutics' Operating Leases stood at $9.2 million in 2021, then fell by 29.98% to $6.4 million in 2022, then surged by 259.42% to $23.1 million in 2023, then dropped by 12.26% to $20.3 million in 2024.